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. However, there are no clear guidelines on the criteria for declaring an institution eligible for performing human ES cell research, other than that it must have a qualified review committee. Therefore, this kind of research is much easier and more widespread in China than in other countries.
According to the guideline, reproductive cloning, the transfer of an embryo into the uterus of a woman or animal and the generation of chimeric human embryos are prohibited (the generation of chimeric human embryos is now allowed under the new Human Fertilisation and Embryology Bill in the United Kingdom 2 ). Human therapeutic cloning is allowed, but the in vitro development of the embryos cannot exceed 14 days. Moreover, human ES cells can only be derived from gametes or embryos at the blastula stage that are left over from in vitro fertilization treatments or are voluntarily donated (from aborted fetuses), and from blastula stage embryos that are created by somatic cell nuclear transfer. As in the United Kingdom, the use of transgenic human embryos is allowed. Unlike the United States, where National Institutes of Health funding is restricted only to a few approved cell lines, there is no limitation on which human ES cell lines can be used. Finally, the privacy of donors and patients involved in stem cell research should be protected and informed written consent should be obtained.
Stem cell research has boomed in China in recent years, with 744 articles on stem cells published between 1998 and 2008, ranking tenth in the list of all publications. Papers and total citation numbers increase every year. However, the quality of research is relatively low, probably owing to the lack of central regulation. The average citation number for a stem cell article from a research group in the United Kingdom is 15.30, 11.37 from the United States, 9.53 from Japan and 8.36 from Germany, but only 3.45 from China (data calculated from ISI Web of Knowledge). Therefore, it is important for China to seek international cooperation. The huge Chinese population and the policies that allow abortion and the isolation of stem cells from aborted fetuses could together provide fruitful sources for the isolation of human ES cells. In addition, the Chinese Government has recently invested additional funding in this area of research, and pilot trials on stem cell-based therapy have since been done 4 . China now lacks stem cell specialists to improve the quality of this research, but international collaboration might solve this problem.
